Plasmid DNA CDMOs — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform

Plasmid DNA manufacturers on CDMO Signal: 22 listed, 22 with a Signal Score. Together they have 65 FDA inspections on file (including 26 NAI, 37 VAI and 2 OAI), 2 FDA warning letters and 117 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

Plasmid DNA CDMOs with the most regulatory evidence on file

Catalent
76.1
Tampa, FL
24 FDA inspections · 39 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-22 · VAI
Warning letter 2025-11-20
See the evidence →
Thermo Fisher Scientific
77.6
Plainville, MA · Alachua, FL · Cambridge, MA
19 FDA inspections · 10 EMA/MHRA GMP certs
Last FDA inspection: 2026-06-30 · NAI
See the evidence →
Charles River Laboratories
86.3
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
9 FDA inspections · 11 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-01 · NAI
See the evidence →
Oxford Biomedica
76.2
Oxford, United Kingdom
2 FDA inspections · 13 EMA/MHRA GMP certs
Last FDA inspection: 2024-06-17 · NAI
See the evidence →
Wacker Biotech
82.9
Jena, DE · Amsterdam, NL · San Diego, CA
1 FDA inspection · 13 EMA/MHRA GMP certs
Last FDA inspection: 2023-12-07 · VAI
See the evidence →
22
CDMOs tracked
22
Fully scored
10
With FDA records
65
FDA inspections
117
EMA/MHRA GMP certs
2
Warning letters

Shortlist plasmid DNA CDMOs with Signal

CDMO Signal is an independent sourcing platform cell therapy, gene therapy, and mRNA sponsors use to compare and shortlist plasmid DNA CDMOs before an RFI. This page is the entry point — the ranked table below is derived from FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals. Use it to narrow the field, then verify fermentation scale, purity specifications, endotoxin control, and lead time directly with the shortlisted suppliers — especially when plasmid is on your program's critical path for viral vector or mRNA supply.

  1. Compare plasmid DNA CDMOs side-by-side on FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals — every number traceable to primary sources.
  2. Filter by regulatory jurisdiction, clean-inspection posture, and clinical-program breadth to your program's shortlisting criteria.
  3. Shortlist Use the ranked results to build your shortlist, then open each profile to review the underlying evidence before contacting suppliers. Follow up with the shortlisted CDMOs to verify fermentation scale, purity specifications, endotoxin control, and lead time directly.

Plasmid DNA is the upstream starting material for viral vectors, mRNA, and DNA therapeutics — which makes plasmid supply a frequent bottleneck for the entire advanced-therapy pipeline. Plasmid CDMOs run microbial (E. coli) fermentation, alkaline lysis, and chromatographic purification to GMP grade.

Selecting a plasmid CDMO turns on GMP vs research grade, supercoiled fraction and purity, fermentation scale, and lead time. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 26 NAI (no action), 37 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (50), UNITED KINGDOM (34), Germany (30), Belgium (12), Austria (12).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 100.0 5 insp · 1 GMP 2026-08-14 · NAI Available —
2
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
3
KB
Durham, NC · Boulder, CO
Hiring · 97+ open roles
84.1 98.5 2 insp · 1 GMP 2026-04-01 · VAI Limited —
4
RP
Keele, UK · Sodertalje, SE
82.9 100.0 0 insp · 3 GMP None on file — —
5
WK
Jena, DE · Amsterdam, NL · San Diego, CA
82.9 100.0 1 insp · 13 GMP 2023-12-07 · VAI — —
6
RB
Hamburg, Germany
82.9 100.0 0 insp · 9 GMP None on file — —
7
KE
Seraing, BE
81.6 99.9 1 insp · 4 GMP 2024-02-26 · VAI — —
8
AE
Fargo, ND
Hiring · 35 open roles
80.3 100.0 1 insp · 0 GMP 2024-11-08 · NAI — —
9
Oklahoma City, OK
78.6 98.2 1 insp · 0 GMP 2026-06-17 · VAI Available —
10
AA
Rockville, MD · Alachua, FL · Munich, DE
78.1 100.0 0 insp · 1 GMP None on file — —
11
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
77.6 93.2 19 insp · 10 GMP 2026-06-30 · NAI Available 2 programs
12
BM
Vienna, Austria
76.8 100.0 0 insp · 12 GMP None on file — —
13
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
76.2 100.0 2 insp · 13 GMP 2024-06-17 · NAI Available 7 programs
14
Tampa, FL
Hiring · 311 open roles
76.1 77.3 24 insp · 39 GMP 2026-05-22 · VAI
Warning letter 2025-11-20
— —
15
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
64.0 — — None on file — —
16
AN
Columbus, OH
63.0 — — None on file Available —
17
BN
Fremont, CA
59.0 — — None on file — —
18
HX
Seoul, KR
Also makes its own products
59.0 — — None on file — —
19
UB
Shanghai, CN · Boston, MA
Hiring · 1 open role
56.5 — — None on file — —
20
NE
Lincoln, NE
56.5 — — None on file — —
21
VX
The Woodlands, TX
56.5 — — None on file — —
22
PF
Bielefeld, Germany
56.5 — — None on file — —
How we score CDMOs →

What to evaluate in a Plasmid DNA CDMO

GMP grade & purity
Confirm GMP (vs research/HQ) grade, supercoiled percentage, and residual host-cell DNA/RNA and endotoxin specs — these gate downstream vector and mRNA quality.
Fermentation scale & yield
Match fermentation scale and yield to your vector or mRNA demand. Ask about high-yield strains and whether scale-up is validated.
Lead time
Plasmid is a common critical-path bottleneck. Evaluate realistic queue and turnaround against your program timeline.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

GMP-grade plasmid vs research-grade — how CDMOs differ

GMP-grade plasmid manufacturing is a materially different discipline from research-grade. GMP requires fermentation under controlled conditions with qualified E. coli strains, endotoxin control (typically <0.1 EU/µg), quantified supercoiled content (>90% is a common target), and full release testing per the intended downstream use. Some CDMOs specialize exclusively in GMP grades; others offer both. Sponsors should also distinguish "GMP-source" plasmid (research-grade produced in GMP facilities) from "full GMP" — some early clinical programs can start on GMP-source but almost all late-stage and commercial work requires full GMP with the accompanying documentation package.

Plasmid CDMOs by downstream use case

Plasmid manufacturing serves three different downstream markets, each with different specs. mRNA template plasmids need to be linearizable and are produced at moderate scale — see the mRNA / LNP CDMO ranking for integrated mRNA+plasmid CDMOs. Viral vector production requires transfection-grade plasmid at moderate scale, often as 2- or 3-plasmid systems — see the AAV CDMO ranking and Lentiviral CDMO ranking. Direct gene therapy uses plasmid as the drug substance itself, at the largest scale and with a distinct regulatory profile. CDMOs vary in which use case they've validated for.

Commercial-scale plasmid — who has the depth?

Commercial-scale plasmid demand has grown sharply alongside mRNA and gene therapy programs. The commercial-scale plasmid filter surfaces CDMOs with top-quartile Signal Score. Commercial plasmid requires validated fermentation at 200L+ scale, chromatographic purification without cesium chloride (which does not scale), and demonstrated endotoxin and residual-DNA control at commercial batch sizes. Sponsors should verify not just capacity headroom but the CDMO's inspection record specifically on the plasmid facility, since plasmid GMP is inspection-verified against strict impurity and identity specs.

How CDMO Signal computes the plasmid DNA ranking

The plasmid DNA Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications, Warning Letter history, and EMA/MHRA GMP certificate density — for plasmid manufacturing this pillar is central, since endotoxin and residual-DNA control are inspection-verified. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint. Financial Stability (20%) draws on public/private status and parent-company backing. Capacity Intelligence (20%) counts the manufacturing sites and modalities listed on the profile; job postings are not a score input. Press announcements and SEC filings are shown on profiles as company signals and do not change any score. Full weightings at cdmosignal.com/methodology.

Plasmid DNA CDMOs — Frequently Asked Questions

How many Plasmid DNA CDMOs have FDA inspection records?
CDMO Signal tracks 10 Plasmid DNA CDMOs with FDA inspection records and 117 EMA/MHRA GMP certificates across the group.
What should I look for in a plasmid DNA CDMO?
Confirm GMP grade and purity specs (supercoiled %, residual host DNA, endotoxin), fermentation scale and yield for your demand, realistic lead time, and a clean FDA and EMA/MHRA record.
Why is plasmid DNA supply often a bottleneck?
Plasmid is the starting material for viral vectors and mRNA, so a single GMP plasmid lot gates multiple downstream steps. Constrained GMP fermentation capacity and long queues make it a frequent critical-path item.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Plasmid DNA shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
mRNA / LNP CDMOs Lentiviral Vector CDMOs AAV / Gene Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector